17 November 2025
17 November 2025
The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.
MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming patent expiry.
The updated Elevidys label now carries a boxed warning regarding the risk of acute liver failure and injury.
Medicxi’s fund comes amid stronger calls from the European biopharma scene for fresh capital.
The fund will participate in follow-on and initial rounds, focusing on biotech and medtech ventures across core markets.
The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
